PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
VRTX vs. XLE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between VRTX and XLE is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

VRTX vs. XLE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vertex Pharmaceuticals Incorporated (VRTX) and Energy Select Sector SPDR Fund (XLE). The values are adjusted to include any dividend payments, if applicable.

-20.00%-15.00%-10.00%-5.00%0.00%5.00%10.00%15.00%SeptemberOctoberNovemberDecember2025February
1.68%
5.25%
VRTX
XLE

Key characteristics

Sharpe Ratio

VRTX:

0.44

XLE:

0.65

Sortino Ratio

VRTX:

0.72

XLE:

0.96

Omega Ratio

VRTX:

1.10

XLE:

1.12

Calmar Ratio

VRTX:

0.48

XLE:

0.80

Martin Ratio

VRTX:

1.31

XLE:

1.76

Ulcer Index

VRTX:

8.49%

XLE:

6.54%

Daily Std Dev

VRTX:

25.20%

XLE:

17.89%

Max Drawdown

VRTX:

-91.77%

XLE:

-71.54%

Current Drawdown

VRTX:

-6.67%

XLE:

-6.66%

Returns By Period

In the year-to-date period, VRTX achieves a 19.76% return, which is significantly higher than XLE's 5.11% return. Over the past 10 years, VRTX has outperformed XLE with an annualized return of 16.13%, while XLE has yielded a comparatively lower 5.29% annualized return.


VRTX

YTD

19.76%

1M

18.46%

6M

1.68%

1Y

12.45%

5Y*

15.13%

10Y*

16.13%

XLE

YTD

5.11%

1M

2.94%

6M

5.25%

1Y

11.66%

5Y*

15.67%

10Y*

5.29%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

VRTX vs. XLE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VRTX
The Risk-Adjusted Performance Rank of VRTX is 5959
Overall Rank
The Sharpe Ratio Rank of VRTX is 6363
Sharpe Ratio Rank
The Sortino Ratio Rank of VRTX is 5252
Sortino Ratio Rank
The Omega Ratio Rank of VRTX is 5353
Omega Ratio Rank
The Calmar Ratio Rank of VRTX is 6767
Calmar Ratio Rank
The Martin Ratio Rank of VRTX is 6161
Martin Ratio Rank

XLE
The Risk-Adjusted Performance Rank of XLE is 2828
Overall Rank
The Sharpe Ratio Rank of XLE is 2626
Sharpe Ratio Rank
The Sortino Ratio Rank of XLE is 2525
Sortino Ratio Rank
The Omega Ratio Rank of XLE is 2626
Omega Ratio Rank
The Calmar Ratio Rank of XLE is 3838
Calmar Ratio Rank
The Martin Ratio Rank of XLE is 2222
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

VRTX vs. XLE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Vertex Pharmaceuticals Incorporated (VRTX) and Energy Select Sector SPDR Fund (XLE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for VRTX, currently valued at 0.44, compared to the broader market-2.000.002.004.000.440.65
The chart of Sortino ratio for VRTX, currently valued at 0.72, compared to the broader market-4.00-2.000.002.004.000.720.96
The chart of Omega ratio for VRTX, currently valued at 1.10, compared to the broader market0.501.001.502.001.101.12
The chart of Calmar ratio for VRTX, currently valued at 0.48, compared to the broader market0.002.004.006.000.480.80
The chart of Martin ratio for VRTX, currently valued at 1.31, compared to the broader market-10.000.0010.0020.0030.001.311.76
VRTX
XLE

The current VRTX Sharpe Ratio is 0.44, which is lower than the XLE Sharpe Ratio of 0.65. The chart below compares the historical Sharpe Ratios of VRTX and XLE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.000.501.001.502.00SeptemberOctoberNovemberDecember2025February
0.44
0.65
VRTX
XLE

Dividends

VRTX vs. XLE - Dividend Comparison

VRTX has not paid dividends to shareholders, while XLE's dividend yield for the trailing twelve months is around 3.19%.


TTM20242023202220212020201920182017201620152014
VRTX
Vertex Pharmaceuticals Incorporated
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
XLE
Energy Select Sector SPDR Fund
3.19%3.36%3.55%3.68%4.21%5.62%5.73%3.54%3.03%2.26%3.39%2.35%

Drawdowns

VRTX vs. XLE - Drawdown Comparison

The maximum VRTX drawdown since its inception was -91.77%, which is greater than XLE's maximum drawdown of -71.54%. Use the drawdown chart below to compare losses from any high point for VRTX and XLE. For additional features, visit the drawdowns tool.


-20.00%-15.00%-10.00%-5.00%0.00%SeptemberOctoberNovemberDecember2025February
-6.67%
-6.66%
VRTX
XLE

Volatility

VRTX vs. XLE - Volatility Comparison

Vertex Pharmaceuticals Incorporated (VRTX) has a higher volatility of 7.45% compared to Energy Select Sector SPDR Fund (XLE) at 5.62%. This indicates that VRTX's price experiences larger fluctuations and is considered to be riskier than XLE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%12.00%14.00%SeptemberOctoberNovemberDecember2025February
7.45%
5.62%
VRTX
XLE
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab